Previous studies showed that ROS1+patients could benefit from pemetrexed‐based chemotherapy.8, 9, 10, 11, 12 Chen et al found that patients with ROS1 fusion had a better ORR (57.9%), higher disease control rate (DCR; 89.5%), and longer PFS (7.5 months) of pemetrexed‐based chemotherapy compared with patients harboring other driver mutations.8 In a retrospective research by Drilon et al, 10 patients with ROS1+NSCLC were treated with pemetrexed‐based systemic therapy and achieved 23 months in the median PFS.13 This evidence concerns the gene ROS1 and non-small cell lung carcinoma.